Festival of Biologics Basel 2020
November 2, 2020
Therapeutic Antibody Hit Generation Using Fully Human Antibody Transgenic Mice RenMab™ and RenLite™ Speaker: Qingcong Lin, CEO of Biocytogen Boston Corp Time: 1:30pm GMT/8:30am ET, November 5th Rapidly therapeutic antibody candidate generation using fully human antibody transgenic mouse RenMab Bispecific antibody hit and candidate generation using common light chain transgenic mouse RenLite Novel antibody hit […]
Celebrating World CRISPR Day
October 29, 2020
Please fill out the form on the left side to consult with our gene editing specialist. To learn more, download gene editing services brochure.
Immuno-Oncology Summit Virtual Summit 2020
October 1, 2020
About the Immuno-Oncology Summit Over the past 8 years, CHI’s Immuno-Oncology Summit has become the leading annual meeting focusing on the latest applied research, providing comprehensive and in-depth coverage across all modalities and stages in the pipeline. Every year, we assemble an international mix of thought leaders and decision makers from industry and academia to […]
Emerging biotechnology company Biocytogen raised 142 million dollars (USD) in support of Project Integrum
September 24, 2020
BEIJING and BOSTON, Sept. 24, 2020 /PRNewswire/ — In August, Beijing Biocytogen Biotechnology Co., Ltd. (“Biocytogen”) announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company. Now, Biocytogen is pleased to announce completion of series D1 Funding, successfully raising 142 million dollars (USD) meant to further secure the implementation of Project Integrum. Project Integrum is a […]
Strategic collaboration agreement reached between Biocytogen and Berkeley Lights for second Beacon Optofluidic system
September 18, 2020
September 14, 2020, Beijing | Beijing Biocytogen Co., Ltd. (“Biocytogen”) reached a collaboration with Berkeley Lights Inc. (“Berkeley Lights”) on the introduction of the second Beacon Optofluidic system. The system will be used in the development of antibody therapeutics to further strengthen the overall drug discovery capabilities of Biocytogen. The two parties will draw on […]
PEGS Boston Virtual Summit
August 20, 2020
Presentation Title: Accelerating Therapeutic Antibody Discovery with Three Distinct Humanized Mouse Models Time: 9:45 AM – 10:10 AM EDT on Monday, August 31 Programs: Antibody for Cancer Therapy Speaker: Qingcong Lin, PhD, CEO, Biocytogen Boston Corp. With a robust immune response, RenMab™ Mouse produces fully-human antibodies with high specificity and diverse epitope coverage. To identify […]
RenMab™ and RenLite™ Models Featured in GEN Magazine
August 19, 2020
RenMab™ Mouse Platform Drives SARS CoV-2 Neutralizing Antibody Cocktail Therapy Towards Clinical Trials in Biocytogen and Eucure Biopharma Partnership
August 13, 2020
[MA, USA and Beijing, China – August] The COVID-19 pandemic has been an inescapable, lethal, and overwhelming aspect of daily human life, threatening health and safety on a global scale. Biocytogen is excited to announce a breakthrough in scientific research and development (R&D) of therapeutic treatment strategy against the novel SARS CoV-2 viral spike protein […]
Webinar: Antibody Discovery Platforms and RenMab Mouse
June 29, 2020
This event has now passed. Now, you can view the Webinar on Youtube. Biocytogen Chief Scientific Officer and Head of Drug Discovery, Benny Yang PhD. will speak on the current landscape of antibody discovery platforms, with special focus on fully human antibody mice. Dr. Yang will explain the advantages and data-backed validation that come with using the RenMabTM Mouse for antibody discovery such as expedited screening of antibody […]
Webinar: Humanized Animal Models for Immunotherapy
June 29, 2020
This event has now passed. Now, you can view the Webinar on Youtube. Topic: Improve Translation of Humanized Animal Models for Immunotherapy Date: Thursday, July 16 2020, 11am-12pm EST. Webinar Description: Despite significant advances have been made in developing novel therapeutics for cancer treatment, only about five percent of new cancer drugs are approved, […]
